To cardiovascular disease and beyond: New therapeutic perspectives of statins in autoimmune diseases and cancer

Current Drug Targets

Volumn 13, Issue 6, 2012, Pages 829-841

  Lopez Pedrera, Chary ^a   Ruiz Limón, Patricia ^a   Valverde Estepa, Araceli ^a   Barbarroja, Nuria ^b   Rodriguez Ariza, Antonio ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

Atherosclerosis; Autoimmune diseases; Cancer; Cardiovascular disease; Inflammation; Statins

Indexed keywords

ATORVASTATIN; CETUXIMAB; CISPLATIN; CYTARABINE; EZETIMIBE; FLUINDOSTATIN; FLUOROURACIL; FOLINIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IDARUBICIN; IRINOTECAN; METHOTREXATE; MEVINOLIN; NITRIC OXIDE; PRAVASTATIN; PREDNISONE; RETINOIC ACID; ROSUVASTATIN; SIMVASTATIN; TRASTUZUMAB; VASCULOTROPIN C;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; AMYOTROPHIC LATERAL SCLEROSIS; ANGIOGENESIS; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPHOSPHOLIPID SYNDROME; APOPTOSIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CANCER CELL; CANCER SURVIVAL; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CELL CYCLE PROGRESSION; CELL FUNCTION; CELL JUNCTION; CELL PROLIFERATION; CHEMORADIOTHERAPY; COLORECTAL CANCER; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HEART INFARCTION; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE ADHERENCE; LIPOPHILICITY; LUNG SMALL CELL CANCER; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCYTE; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLEIOTROPY; PROTEIN PRENYLATION; RADIATION DOSE; RADIOSENSITIZATION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; NEOPLASMS;

EID: 84860820321     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012800564112     Document Type: Review

References (139)

1. Chalubinski M, Broncel M. Influence of statins on effector and regulatory immune mechanisms and their potential clinical relevance in treating autoimmune disorders. Med Sci Monit 2010; 16: RA245-RA251.
2. Fritz G. Targeting the mevalonate pathway for improved anticancer therapy. Curr Cancer Drug Targets 2009; 9: 626-638.
3. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mchanisms and clinical results. Trends Mol Med 2008; 14: 37-44.
4. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006; 6: 358-370.
5. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118.
6. Smaldone C, Brugaletta S, Pazzano V, Liuzzo G. Immunomodulator activity of 3-hydroxy-3-methilglutaryl-CoA inhibitors. Cardiovasc Hematol Agents Med Chem 2009; 7: 279-924.
7. rd, Braciale TJ. Cutting edge: lipid raft integrity affects the efficiency of MHC class I tetramer binding and cell surface TCR arrangement on CD8+ T cells. J Immunol 2001; 166: 7009-7013.
8. Cheng PC, Dykstra ML, Mitchell MN, Pierce SK. A role for lipid rafts in B cell antigen receptor signaling and antigen targeting. J Exp Med 1999; 190: 1549-1560.
9. Goebel J, Forrest K, Flynn D, Rao R, Roszman TL. Lipid rafts, major histocompatibility complex molecules, and immune regulation. Hum Immunol 2002; 63: 813-820.
10. Hillyard DZ, Cameron AJ, McDonalds KJ, Thomson J, McIntyre A, Shiels PJ. Simvastatin inhibits lymphocyte function in normal subjects and patients with cardiovascular disease. Atherosclerosis 2004; 175: 305-313.
11. Cortellaro M, Cofrancesco E, Arbustini E, et al. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study. Thromb Haemost 2002; 88: 41-47.
12. Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373: 1175-1182.
13. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360: 1851-1861.
14. Undas A, Brummel-Ziedins E, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol 2005; 25: 1-8.
15. Ghittoni R, Napolitani G, Benati D, et al. Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases. Eur J Immunol 2006; 36: 2885-2893.
16. Holling TM, Schooten E, van den Elsen PJ. Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men. Hum Immunol 2004; 65: 282-290.
17. Kuipers HF, Biesta PJ, Groothuis TA, et al. Statins affect T cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterol-containing microdomains. Hum Immunol 2005; 66: 653-665.
18. Ghittoni R, Patrussi L, Pirozzi K, et al. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. FASEB J 2005; 19: 605-607.
19. Dunn SE, Youssef S, Goldstein MJ, et al. Isoprenoids determine Th1/Th2 fate in pathogenic T cells providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 2006; 203: 401-412.
20. Canalli AA, Proença RF, Franco-Penteado CF, et al. Participation of Mac-1, LFA-1 and VLA-4 integrins in the in vitro adhesion of sickle cell disease neutrophils to endothelial layers, and reversal of adhesion by simvastatin. Haematologica 2011; 96:526-533.
21. Blank N, Schiller M, Krienke S, et al. Atorvastatin inhibits T cell activation through 3-hydroxy-3-methylglutaryl coenzyme A reductase without decreasing cholesterol synthesis. J Immunol 2007; 179:3613-3621.
22. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994; 84: 2068-2101.
23. Dustin ML, Springer TA. T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature 1989; 341: 619-624.
24. Greenwood J, Walters CE, Pryce G, et al. Lovastatin inhibits brain endothelial Rho-dependent lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J 2003; 17: 905-907.
25. Yoshida M, Sawada T, Ishii H, et al. HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism. Arterioscler Thromb Vasc Biol 2001; 21: 1165-1171.
26. Rezaie-Majd A, Prager GW, Bucek RA, et al. Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2003; 23: 397-403.
27. Turner NA, O'Regan DJ, Ball SG, Porter KE. Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. FASEB J 2005; 19: 804-806.
28. Antoniades C, Bakogiannis C, Leeson P, et al. Rapid, Direct Effects of Statin Treatment on Arterial Redox State and Nitric Oxide Bioavailability in Human Atherosclerosis via Tetrahydrobiopterin-Mediated Endothelial Nitric Oxide Synthase Coupling. Circulation. 2011; 124: 335-345.
29. Bath PMW, Hassall DG, Gladwin AM, Palmer RMJ, Martin JF. Nitric oxide and prostacyclin: divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. Arterioscler Thromb Vasc Biol 1991; 11: 254-260.
30. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991; 88: 4651-4655.
31. Takahashi M, Ikeda U, Masuyama J, Funayama H, Kano S, Shimada K. Nitric oxide attenuates adhesion molecule expression in human endothelial cells. Cytokine 1996; 8: 817-821.
32. Spiecker M, Peng HB, Liao JK. Inhibition of endothelial vascular cell adhesion molecule-1 expression by nitric oxide involves the induction and nuclear translocation of IκBα. J Biol Chem 1997; 272: 30969-30974.
33. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995; 96: 60-68.
34. Youssef SO, Stuve JC, Patarroyo PJ, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 78-84.
35. Zhang X, Jin J, Peng X, Ramgolam VS, Markovic-Plese S. Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol 2008; 180: 6988-6996.
36. Chase AJ, Bond M, Crook MF, Newby AC. Role of nuclear factor-kappa B activation in metalloproteinase-1, -3, and -9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo. Arterioscler Thromb Vasc Biol 2002; 22: 765-771.
37. Cuccurullo C, Lezzi A, Fazia ML, et al. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol 2006; 26: 2716-2723.
38. Bruni F, Puccetti L, Pasqui AL, et al. Different effect induced by treatment with several statins on monocyte tissue factor expression in hypercholesterolemic subjects. Clin Exp Med 2003; 3: 45-53.
39. Espinosa G, Cervera R, Font J, Shoenfeld Y. Antiphospholipid syndrome: Pathogenic mechanisms. Autoimmun Rev 2003; 2: 86-93.
40. Cuadrado MJ, López-Pedrera C, Khamashta MA, et al. Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997; 40: 834-841.
41. López-Pedrera C, Buendía P, Cuadrado MJ, et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 2006; 54: 301-311.
42. Bohgaki M, Atsumi T, Yamashita Y, et al. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2Glycoprotein I antibodies. Int Immunol 2004; 16: 1633-1641.
43. Redecha P, Franzke CW, Ruf W, et al. Neutrophil activation by the tissue factor/factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J Clin Invest 2008; 118: 3453-3461.
44. López-Pedrera C, Aguirre MA, Buendía P, et al. Differential expression of proteaseactivated receptors in monocytes from patients with primary Antiphospholipid syndrome. Arthritis Rheum 2010; 62: 869-877.
45. Rao LV, Pendurthi UR. Tissue factor-factor VIIa signaling. Arterioscler Thromb Vasc Biol 2005; 25: 47-56.
46. Chu AJ. Tissue factor mediates infl ammation. Arch Biochem Biophys 2005; 440: 123-132.
47. Wang H, Keiser JA. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flit-1. Circ Res 1998; 83: 832-840.
48. Cuadrado MJ, Buendía P, Velasco F, et al. Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome. J Thromb Haemost 2006; 4: 2461-2469.
49. Dupuy E, Habib A, Lebret M, et al. Thrombin induces angiogenesis and vascular endothelial growth factor expression in human endothelial cells: possible relevance to HIF-1alpha. J Thromb Haemost 2003; 1: 1096-1102.
50. Hwang KK, Grossman JM, Visvanathan S, et al. Identification of anti-thrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin. J Immunol 2001; 167: 7192-7198.
51. Tsopanoglou NE, Maragoudakis ME. Role of thrombin in angiogenesis and tumor progression. Semin Thromb Hemost 2004; 30: 63-69.
52. López-Pedrera C, Cuadrado MJ, Hernández V, et al. Proteomic analysis in monocytes of antiphospholipid syndrome patients: deregulation of proteins related to the development of thrombosis. Arthritis Rheum 2008; 58: 2835-2844.
53. Jurcut C, Jurcut R, Tanasescu C. Cardiovascular risk and rheumatoid arthritis: from mechanisms of atherosclerosis to therapeutic approach. Rom J Int Med 2004; 42: 659-669.
54. Bruce IN. Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin. Best Pract Res Clin Rheumatol 2005; 19: 823-838.
55. Soltesz P, Veres K, Lakos G, Kiss E, Muszbek L, Szegedi G. Evaluation of clinical and laboratory features of antiphospholipid syndrome: a retrospective study of 637 patients. Lupus 2003; 12: 302-307.
56. Jimenez S, García-Criado MA, Tassies D, et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology 2005; 44: 756-761.
57. Shoenfeld Y, Sherer Y, George J, Harats D. Autoantibodies associated with atherosclerosis. Ann Med 2000; 32(Suppl. I): 37-40.
58. Vaarala O. Antiphospholipid antibodies and atherosclerosis. Lupus 1996; 5: 442-447.
59. Veres K, Lakos G, Kerenyi A, et al. Antiphospholipid antibodies in acute coronary syndrome. Lupus 2004; 13: 423-427.
60. Undas A, Celiska-Lowenhoff M, Kaczor M, Musial J. New nonlipid effects of statins and their clinical relevance in cardiovascular disease. Thromb Haemost 2004; 91: 1065-1077.
61. Krysiak R, Okopien B, Herman ZS. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 2003; 63: 1821-1854.
62. Undas A, Brummel-Ziedins E, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol 2005; 25: 1-8.
63. Meroni PL, Raschi E, Testoni C, et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 2001; 44: 2870-2878.
64. Ferrara DE, Liu X, Espinola RG, et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 2003; 48: 3272-3279.
65. Ferrara DE, Swerlick R, Casper K, et al. Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost 2004; 2: 1558-1563.
66. Martínez-Martínez LA, Amigo MC, Orozco A, et al. Effect of rosuvastatin on VCAM-1 expression by HUVEC exposed to APS serum in an in vitro model. Clin Exp Rheumatol 2007; 25: 18-19.
67. López-Pedrera C, Ruiz-Limón P, Aguirre MA, et al. Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. Ann Rheum Dis 2011; 70: 675-682.
68. Redecha P, Franzke CW, Ruf W, et al. Neutrophil activation by the tissue factor/factor VIIa/PAR2 axis mediates foetal death in a mouse model of antiphospholipid syndrome. J Clin Invest 2008; 118: 3453-3461.
69. Jajoria P, Murthy V, Papalardo E, et al. Statins for the treatment of antiphospholipid syndrome? Ann NY Acad Sci 2009; 1173: 736-745.
70. Ridker PM, Danielson E, Fonseca FA. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 20: 2195-2107.
71. Lopez-Pedrera Ch, Aguirre MA, Barbarroja N, Cuadrado MJ. Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches. J Biomed Biotech 2010; doi: 10.1155/2010/607084.
72. Ferreira GA, Navarro TP, Telles RW, et al. Atorvastatin therapy improves endothelialdependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology 2007; 46: 1560-1565.
73. Kotyla PJ, Sliwinska-Kotyla B, Kucharz EJ. TNF- α as a potential target in the treatment of systemic lupus erythematosus: a role for the HMG-CoA reductase inhibitor simvastatin. Journal of Rheumatology 2006; 33: 2361-2363.
74. Vera-Lastra O, Mendez OL, Jara LJ, et al. Effects of ezetimibe plus pravastatin on endothelial dysfunction in patients with systemic lupus erythematosus (pilot study) [abstract]. Arthritis Rheum 2009; 60(Suppl 10):1564.
75. Graham KL, Lee LY, Higgins JP, Steinman L, Utz PJ, Ho PP. Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus. Arthritis and Rheumatism 2008; 58: 2098-2104.
76. Norby GE, Holme I, Fellström B, et al. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus a randomized placebo controlled study. Arthritis and Rheumatism 2009; 60: 1060-1064.
77. Petri MA, Kiani AN, Post W, Christopher-Stine L, Magder LS. Lupus Atherosclerosis prevention study (LAPS). Ann Rheum Dis 2011; 70: 760-765.
78. Suchak R, Benson K, Swale V. Statin-induced Ro/SSa-positive subacute cutaneous lupus erythematosus. Clin. Exp. Dermatol 2007; 32: 589-591.
79. Sarzi-Puttini P, Atzeni F, Capsoni F, Lubrano E, Doria A. Drug-induced lupus erythematosus. Autoimmunity 2005; 38: 507-518.
80. Symmons DPM, Gabriel SE. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol 2011; 7:399-408.
81. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303-1307.
82. Gerli R, Sherer Y, Bocci EB, et al. Precocious atherosclerosis in rheumatoid arthritis: Role of traditional and disease-related cardiovascular risk factors. Ann NY Acad Sci 2007; 1108: 372-381.
83. del Rincón I, Freeman GL, Haas RW, et al. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherothrombosis. Arthritis Rheum 2005; 52: 3413-3423.
84. Dhawan SS, Quyyumi AA. Rheumatoid arthritis and cardiovascular disease. Curr Atheroscler Rep 2008; 10: 128-133.
85. Sherer Y, Shoenfeld Y. Mechanisms of disease: Atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2006; 2: 99-106.
86. Zal B, Kaski JC, Arno G, et al. Heat-shok protein 60-reactive CD41CD28null T cells in patients with acute coronary syndrome. Circulation 2004; 109: 1230-1235.
87. Szekanecz Z, Kerekes G, Dér H, et al. Accelerated atherosclerosis in rheumatoid arthritis. Ann NY Acad Sci 2007; 1108: 349-358.
88. McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo controlled trial. Lancet 2004; 363: 2015-2021.
89. Shirinsky IV, Zheltova OI, Solovyova NY, Kozlov VA, Shirinsky VS. Changes in disease activity, cytokine production, and proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis after simvastatin treatment. Scand J Rheumatol 2009; 38: 23-27.
90. El-Barbary AM, Hussein MS, Rageh EM, Hamouda HE, Wagih AA, Ismail RG. Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis. J Rheumatol 2011; 38: 229-235.
91. Tikiz C, Utuk O, Pirildar T, et al. Effects of Angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with long term rheumatoid arthritis. J Rheumatol 2005; 32: 2095-2101.
92. Okamoto H, Koizumi K, Kamitsuji S, et al. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J Rheumatol 2007; 34: 964-968.
93. Maki-Petaja KM, Booth AD, Hall FC, et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 2007; 50: 852-858.
94. Toms TE, Panoulas VF, Douglas KM, et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substancial Ander treatment of lipid associated cardiovascular risk? Ann Rheum Dis 2009; 69:683-688.
95. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res 2003; 9: 10-19.
96. Overmeyer JH, Maltese WA. Death pathways triggered by activated Ras in cancer cells. Front Biosci 2011; 16: 1693-1613.
97. Vega FM, Ridley AJ. Rho GTPases in cancer cell biology. FEBS Lett 2008; 582: 2093-2101.
98. Taras D, Blanc JF, Rullier A, et al. Pravastatin reduces lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity. J Hepatol 2007; 46: 69-76.
99. Kidera Y, Tsubaki M, Yamazoe Y, et al. Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho-associated coiled-coil-containing protein kinase pathway. J Exp Clin Cancer Res 2010; 29: 127.
100. Relja B, Meder F, Wang M, et al. Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK. Int J Oncol 2011; 38: 879-885.
101. Mandal CC, Ghosh-Choudhury N, Yoneda T, Choudhury GG and Ghosh-Choudhury N. Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J Biol Chem 2011; 286: 11314-11327.
102. Fromigue O, Hamidouche Z, Marie PJ. Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion. J Biol Chem 2008; 283: 30549-30556.
103. Fromigue O, Hamidouche Z, Vaudin P, et al. CYR61 downregulation reduces osteosarcoma cell invasion, migration, and metastasis. J Bone Miner Res 2011; 26: 1533-1542.
104. Yang PM, Liu YL, Lin YC, Shun CT, Wu MS, Chen CC. Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies. Cancer Res 2010; 70: 7699-7709.
105. Parikh A, Childress C, Deitrick K, Lin Q, Rukstalis D, Yang W. Statin-induced autophagy by inhibition of geranylgeranyl biosynthesis in prostate cancer PC3 cells. Prostate 2010; 70: 971-981.
106. Frick M, Dulak J, Cisowski J, et al. Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells. Atherosclerosis 2003; 170: 229-236.
107. Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation 2002; 105: 739-745.
108. Feleszko W, Balkowiec EZ, Sieberth E, et al. Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis. Int J Cancer 1999; 81: 560-567.
109. Zhao TT, Trinh D, Addison CL, Dimitroulakos J. Lovastatin inhibits VEGFR and AKT activation: synergistic cytotoxicity in combination with VEGFR inhibitors. PLoS One 2010; 5:e12563.
110. Hindler K, Cleeland CS, Rivera E, Collard CD. The role of statins in cancer therapy. Oncologist 2006; 11: 306-315.
111. Wu J, Wong WW, Khosravi F, Minden MD, Penn LZ. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 2004; 64: 6461-6468.
112. Minden MD, Dimitroulakos J, Nohynek D, Penn LZ. Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia. Leuk Lymphoma 2001; 40: 659-662.
113. Dimitroulakos J, Nohynek D, Backway KL, et al. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood 1999; 93: 1308-1318.
114. Dimitroulakos J, Thai S, Wasfy GH, Hedley DW, Minden MD, Penn LZ. Lovastatin induces a pronounced differentiation response in acute myeloid leukemias. Leuk Lymphoma 2000; 40: 167-178.
115. Burke LP, Kukoly CA. Statins induce lethal effects in acute myeloblastic leukemia [corrected] cells within 72 hours. Leuk Lymphoma 2008; 49: 322-330.
116. Lishner M, Bar-Sef A, Elis A, Fabian I. Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell lines. J Investig Med 2001; 49: 319-324.
117. Van der WK, de Jonge-Peeters SD, Kuipers F, de Vries EG, Vellenga E. Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples. Clin Cancer Res 2009; 15: 3076-3083.
118. Kornblau SM, Banker DE, Stirewalt D, et al. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood 2007; 109: 2999-3006.
119. Sassano A, Katsoulidis E, Antico G, et al. Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res 2007; 67: 4524-4532.
120. Tomiyama N, Matzno S, Kitada C, Nishiguchi E, Okamura N, Mat-suyama K. The possibility of simvastatin as a chemotherapeutic agent for all-trans retinoic acid-resistant promyelocytic leukemia. Biol Pharm Bull 2008; 31: 369-374.
121. Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG, Holt PR. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 1999; 5: 2223-2229.
122. Wang W, Collie-Duguid E, Cassidy J. Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines. FEBS Lett 2002; 531: 415-420.
123. Kodach LL, Jacobs RJ, Voorneveld PW, et al. Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell 'stemness' via the bone morphogenetic protein pathway. Gut 2011.
124. Lee J, Jung KH, Park YS, et al. Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. Cancer Chemother Pharmacol 2009; 64: 657-663.
125. Han JY, Lim KY, Yu SY, Yun T, Kim HT, Lee JS. A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer. Cancer 2011; 117: 2178-2185.
126. Martirosyan A, Clendening JW, Goard CA, Penn LZ. Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance. BMC Cancer 2010; 10:103.
127. Taylor-Harding B, Orsulic S, Karlan BY, Li AJ. Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells. Gynecol Oncol 2010; 119: 549-556.
128. Kamigaki M, Sasaki T, Serikawa M, et al. Statins induce apoptosis and inhibit proliferation in cholangiocarcinoma cells. Int J Oncol 2011; 39: 561-568.
129. Lee J, Lee I, Han B, et al. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. J Natl Cancer Inst 2011; 103: 674-688.
130. Huether A, Hopfner M, Baradari V, Schuppan D, Scherubl H. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol 2005; 70: 1568-1578.
131. Budman DR, Tai J, Calabro A. Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitro. Breast Cancer Res Treat 2007; 104: 93-101.
132. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 2004; 59: 928-942.
133. Chang IY, Youn CK, Kim HB, et al. Oncogenic H-Ras up-regulates expression of Ku80 to protect cells from gamma-ray irradiation in NIH3T3 cells. Cancer Res 2005; 65: 6811-619.
134. Miller AC, Kariko K, Myers CE, Clark EP, Samid D. Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation. Int J Cancer 1993; 53: 302-307.
135. Sanli T, Liu C, Rashid A, et al. Lovastatin sensitizes lung cancer cells to ionizing radiation: modulation of molecular pathways of radioresistance and tumor suppression. J Thorac Oncol 2011; 6: 439-450.
136. Kollmeier MA, Katz MS, Mak K, et al. Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2011; 79: 713-718.
137. Soto DE, Daignault S, Sandler HM, Ray ME. No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer. Urology 2009; 73: 158-162.
138. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statins trials. Lancet 2010; 375:735-742.
139. Goldstein MR, Mascitelli L, Pezzetta F. Do statins prevent or promote cancer? Curr Oncol 2008; 15(2): 76-87.